Teng Feifei, Tsien Christina I, Lawrence Theodore S, Cao Yue
Department of Radiation Oncology, Ann Arbor, United States; Department of Radiation Oncology, Shandong Cancer Hospital, Shandong University, Jinan, China.
Department of Radiation Oncology, Washington University, St. Louis, United States.
Radiother Oncol. 2017 Oct;125(1):89-93. doi: 10.1016/j.radonc.2017.08.006. Epub 2017 Aug 20.
Blood-tumor barrier is a limiting factor for effectiveness of systemic therapy to brain metastases. This study aimed to assess the extent and time course of BTB opening in BM following whole-brain radiotherapy (WBRT) or stereotactic radiosurgery (SRS) to determine optimal timing for systemic therapy.
30 patients received WBRT or SRS and a total of 64 metastatic lesions were analyzed. Dynamic contrast-enhanced MRI were acquired, to quantify a transfer constant (K), pre-RT, 1-2weeks after starting RT (Wk1-2), and 1-month post-RT (1M post-RT). Lesions were categorized as either low or high permeability based upon the pre-RT percentage volume of a lesion with K>0.005min (%V) less or greater than 50%. Time-course changes of %V after RT were analyzed.
Fifty-seven lesions had high-permeability and seven had low-permeability at baseline. Intra-patient and inter-lesion heterogeneity was observed in six patients who had both low- (n=7) and high-permeability lesions (n=10). Also, lesion permeability showed a significant size-effect at baseline. For high-permeability lesions, either received WBRT (n=43) or SRS (n=14), %V decreased non-significantly following RT (from 85.4% pre-RT to 76.9% 1M post-RT). For low-permeability lesions (n=7, all received WBRT), %V increased from 5.6% pre-RT to 30.2% at Wk1-2 and to 52.6% 1M-post (p=0.01).
Our preliminary results suggest that 2-4weeks after RT, when BTB opening is high for both low- and high-permeability brain metastatic lesions, could be optimal time to start systemic therapy.
血肿瘤屏障是脑转移瘤全身治疗有效性的限制因素。本研究旨在评估全脑放疗(WBRT)或立体定向放射外科治疗(SRS)后脑转移瘤中血肿瘤屏障开放的程度和时间进程,以确定全身治疗的最佳时机。
30例患者接受了WBRT或SRS治疗,共分析了64个转移瘤病灶。进行动态对比增强MRI检查,以量化放疗前、放疗开始后1 - 2周(第1 - 2周)和放疗后1个月(放疗后1个月)的转运常数(K)。根据放疗前K>0.005min的病灶体积百分比(%V)小于或大于50%,将病灶分为低通透性或高通透性。分析放疗后%V的时间进程变化。
基线时57个病灶为高通透性,7个病灶为低通透性。在6例同时有低通透性(n = 7)和高通透性病灶(n = 10)的患者中观察到患者内和病灶间的异质性。此外,病灶通透性在基线时显示出显著的大小效应。对于接受WBRT(n = 43)或SRS(n = 14)的高通透性病灶,放疗后%V无显著下降(从放疗前的85.4%降至放疗后1个月的76.9%)。对于低通透性病灶(n = 7,均接受WBRT),%V从放疗前的5.6%增加到第1 - 2周的30.2%,并在放疗后1个月增加到52.6%(p = 0.01)。
我们初步结果表明,放疗后2 - 4周,低通透性和高通透性脑转移瘤的血肿瘤屏障开放程度均较高,可能是开始全身治疗的最佳时机。